Filing Details
- Accession Number:
- 0001209191-17-063878
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-12-05 16:08:13
- Reporting Period:
- 2017-12-01
- Accepted Time:
- 2017-12-05 16:08:13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-12-01 | 4,000 | $5.50 | 19,977 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-12-01 | 1,865 | $171.72 | 18,112 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-12-01 | 1,335 | $172.77 | 16,777 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-12-01 | 800 | $173.48 | 15,977 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2017-12-01 | 4,000 | $0.00 | 4,000 | $5.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
79,151 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- The range of prices for the transaction reported on this line was $171.25 to $172.20. The average weighted price was $171.7157. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was $172.2500 to $173.2250. The average weighted price was $172.7713. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was $173.25 to $174.00. The average weighted price was $173.4750. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.